JNJ Verdict: Johnson & Johnson Must Pay $55 Million in Talc-Powder Cancer Case

Johnson & Johnson (JNJ) has been ordered to pay $55 million to Gloria Ristesund in a talc-powder lawsuit concerning ovarian cancer. More 

7 Pharmaceuticals Stocks to Buy Now

7 Pharmaceuticals stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an "A" ("strong buy") or "B" overall ("buy"). More 

Microsoft Corporation (MSFT) and Johnson & Johnson (JNJ): The Last AAA Survivors

Now there are only two remaining AAA stocks: Microsoft (MSFT) and Johnson & Johnson (JNJ). Here's an overview of their long-term survivability. More 

Johnson & Johnson (JNJ): The Dividend King of Kings

Reliable for more than 50 years, Johnson & Johnson is a dividend king. And given its recent Q1 earnings beat and increased guidance for the year, it's bound to stay on the throne for a long time. More 

8 Bargain Dividend Stocks to Buy Now

Don't chase momentum amid the market's bull run. Instead, buy cheap protection with these eight bargain dividend stocks to buy now. More 

Why JPMorgan Chase & Co. Can Double Your Investment (JPM)

The banking industry is changing, and JPMorgan is poised to deliver strong long-term returns for investors willing to understand these JPM dynamics... More 

Why Johnson & Johnson (JNJ), Panera Bread Co (PNRA) and Spirit Airlines Incorporated (SAVE) Are 3 of Today’s Best Stocks

Guidance and analyst upgrades helped JNJ, PNRA and SAVE become three of today's best stocks. More